Enovix Corporation (NASDAQ:ENVX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Enovix has a consensus analyst rating of “Moderate Buy”, with 7 buy ratings, 1 hold, and 2 sell ratings. The average 12-month price target is about $12.64.
• The company’s latest quarter beat expectations, posting EPS of -$0.14 versus estimates of -$0.15 and revenue of $7.6 million, up 49.1% year over year. Management also pointed to revenue growth and strategic progress, though the business remains loss-making.
• Despite the positive earnings beat, analysts have cut price targets across several firms, and investors remain concerned about widening losses and the timeline for commercialization. Shares were trading around $6.11, well below the stock’s 52-week high of $16.49.

Enovix Corporation (NASDAQ:ENVX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten brokerages that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $12.6364.

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. lowered Enovix from a "neutral" rating to an "underweight" rating in a research report on Wednesday, May 6th. TD Cowen reiterated a "buy" rating on shares of Enovix in a research report on Thursday. Benchmark dropped their price objective on Enovix from $25.00 to $15.00 and set a "buy" rating on the stock in a research note on Thursday. B. Riley Financial dropped their price objective on Enovix from $17.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, March 2nd. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Enovix in a research note on Friday, April 10th.

Institutional Trading of Enovix

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Caitlin John LLC purchased a new position in shares of Enovix during the third quarter valued at $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Enovix during the fourth quarter valued at $30,000. Parallel Advisors LLC grew its holdings in shares of Enovix by 51.9% during the third quarter. Parallel Advisors LLC now owns 3,926 shares of the company's stock valued at $39,000 after buying an additional 1,342 shares in the last quarter. CWM LLC grew its holdings in shares of Enovix by 95.4% during the fourth quarter. CWM LLC now owns 6,081 shares of the company's stock valued at $44,000 after buying an additional 2,969 shares in the last quarter. Finally, Calamos Advisors LLC purchased a new position in shares of Enovix during the first quarter valued at $60,000. Institutional investors own 50.92% of the company's stock.

Key Enovix News

Here are the key news stories impacting Enovix this week:

• Positive Sentiment: Enovix’s Q1 results beat revenue expectations and the company reported a smaller-than-expected loss, while management highlighted revenue growth and strategic progress on the earnings call. Enovix Corp (ENVX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Alignments
• Positive Sentiment: Unusually heavy call option activity suggests some traders are betting on a rebound in Enovix shares. Enovix NASDAQ: ENVX Price Target Cut to $21.00 by Analysts at Oppenheimer
• Neutral Sentiment: Oppenheimer, Benchmark, Craig Hallum, and TD Cowen all reduced their price targets on Enovix, but most still kept constructive ratings, signaling lower valuation expectations rather than a full thesis change. Enovix NASDAQ: ENVX Given New $15.00 Price Target at Benchmark Enovix NASDAQ: ENVX Price Target Lowered to $8.00 at Craig Hallum Enovix NASDAQ: ENVX Price Target Cut to $7.00 by Analysts at TD Cowen
• Negative Sentiment: Investors are also focused on Enovix’s widening losses and the uncertain timeline for commercialization, which appeared to weigh on the stock after earnings. Enovix sinks as losses widen; commercialization timeline remains in focus

Enovix Trading Down 3.0%

Shares of ENVX stock opened at $6.11 on Friday. The company has a debt-to-equity ratio of 1.90, a quick ratio of 8.13 and a current ratio of 8.34. Enovix has a 1 year low of $4.61 and a 1 year high of $16.49. The stock has a fifty day moving average of $5.82 and a two-hundred day moving average of $7.10. The firm has a market capitalization of $1.33 billion, a PE ratio of -7.36 and a beta of 2.24.

Enovix (NASDAQ:ENVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. Enovix had a negative return on equity of 63.25% and a negative net margin of 499.64%.The company had revenue of $7.60 million during the quarter, compared to analyst estimates of $6.95 million. During the same quarter in the previous year, the firm posted ($0.15) EPS. The firm's quarterly revenue was up 49.1% on a year-over-year basis. Enovix has set its Q2 2026 guidance at -0.170--0.130 EPS. As a group, research analysts expect that Enovix will post -0.81 EPS for the current year.

Enovix Company Profile

Enovix Corporation NASDAQ: ENVX develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.